Health authorities in Australia and Europe have warned that GLP-1 weight-loss drugs may be linked to rare cases of permanent vision loss.
These warnings are critical because the medications, including Ozempic, Wegovy, and Mounjaro, have seen a massive surge in global popularity for treating obesity and diabetes. Any risk of permanent disability could impact the treatment plans of millions of patients.
The Therapeutic Goods Administration in Australia and the European Medicines Agency have both reported instances of serious eye disorders among users [1, 4]. While the occurrences are described as rare, the potential for total blindness has prompted officials to alert the public [2, 3].
In Australia, hundreds of thousands of people are currently taking Ozempic, Wegovy, or Mounjaro [1]. The scale of adoption increases the likelihood that even rare side effects will appear in a significant number of patients.
Reports regarding these vision complications first surfaced in early 2025 [5]. The conditions can manifest as sudden blurring or total loss of sight, which requires immediate intervention to prevent permanent damage.
Medical professionals emphasize the urgency of these symptoms. "Sudden vision loss or blurring while taking GLP-1s should be treated as a medical emergency," an expert said [3].
Patients are advised to contact their healthcare providers immediately if they notice any changes in their sight. Regulators continue to monitor the safety profiles of these drugs as more data becomes available from global health systems [1, 4].
“Sudden vision loss or blurring while taking GLP-1s should be treated as a medical emergency.”
The emergence of rare but severe side effects like permanent blindness highlights the tension between the rapid adoption of GLP-1 agonists and the long-term understanding of their safety profiles. As these drugs move from specialized diabetes treatments to widespread weight-loss tools, regulators must balance the significant metabolic benefits against emerging risks to other organ systems, such as the eyes.
